The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan

碩士 === 長庚大學 === 企業管理研究所 === 96 === The emergency needs of adopting external supports from other resources of biotechnology industry are noticed especially while companies acquiring break-through in product development research, clinical trials, product commercialization, marketing, and tackling prob...

Full description

Bibliographic Details
Main Authors: Yi Ru Chen, 陳怡如
Other Authors: K. H. Hsu
Format: Others
Published: 2008
Online Access:http://ndltd.ncl.edu.tw/handle/77208370580070317324
id ndltd-TW-096CGU05121022
record_format oai_dc
spelling ndltd-TW-096CGU051210222016-05-13T04:15:00Z http://ndltd.ncl.edu.tw/handle/77208370580070317324 The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan 國內生技醫藥產業策略聯盟之優先因素評估 Yi Ru Chen 陳怡如 碩士 長庚大學 企業管理研究所 96 The emergency needs of adopting external supports from other resources of biotechnology industry are noticed especially while companies acquiring break-through in product development research, clinical trials, product commercialization, marketing, and tackling problems in strategic management. The number of strategic alliance was increasing, which demonstrated the fast developing status of biotech industry in Taiwan. However, the motivations of initiating strategic alliance with external resources were found varied from different stages and types of biotech companies. Some may want to adopt scarce resources or share cost and risk of development; others may seek complementary resources or gain market competitive advantages. Therefore, the study of determinants and prioritization related to decision making of strategic alliance among particular parts of biotech companies are warranted for industrial successfulness. This study has followed steps from factors construction to application of analytic hierarchy process for the research protocol. Biotech companies in the categories of genetic engineering protein drugs, allergic pharmaceutics, human blood substitutes, and vaccine products were selected as study subjects. Twenty criteria/questions in four constructs, such as criteria for alliances, industrial characteristics, technologies and products, and needs of external supports, were constructed from literature review and experts validation in the measurement. The priority for determining strategic alliance was concluded accordingly as: 1) Technology Platform or equipment. 2) Improve product competitive ability. 3) technical knowledge and ability compatible or complementary. 4) Complementarity of capabilities. 5) Professional employee in a specialized field. Finally, this study provides valuable information for this industry to choose their appropriate partners for future developments. K. H. Hsu 許光宏 2008 學位論文 ; thesis 131
collection NDLTD
format Others
sources NDLTD
description 碩士 === 長庚大學 === 企業管理研究所 === 96 === The emergency needs of adopting external supports from other resources of biotechnology industry are noticed especially while companies acquiring break-through in product development research, clinical trials, product commercialization, marketing, and tackling problems in strategic management. The number of strategic alliance was increasing, which demonstrated the fast developing status of biotech industry in Taiwan. However, the motivations of initiating strategic alliance with external resources were found varied from different stages and types of biotech companies. Some may want to adopt scarce resources or share cost and risk of development; others may seek complementary resources or gain market competitive advantages. Therefore, the study of determinants and prioritization related to decision making of strategic alliance among particular parts of biotech companies are warranted for industrial successfulness. This study has followed steps from factors construction to application of analytic hierarchy process for the research protocol. Biotech companies in the categories of genetic engineering protein drugs, allergic pharmaceutics, human blood substitutes, and vaccine products were selected as study subjects. Twenty criteria/questions in four constructs, such as criteria for alliances, industrial characteristics, technologies and products, and needs of external supports, were constructed from literature review and experts validation in the measurement. The priority for determining strategic alliance was concluded accordingly as: 1) Technology Platform or equipment. 2) Improve product competitive ability. 3) technical knowledge and ability compatible or complementary. 4) Complementarity of capabilities. 5) Professional employee in a specialized field. Finally, this study provides valuable information for this industry to choose their appropriate partners for future developments.
author2 K. H. Hsu
author_facet K. H. Hsu
Yi Ru Chen
陳怡如
author Yi Ru Chen
陳怡如
spellingShingle Yi Ru Chen
陳怡如
The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan
author_sort Yi Ru Chen
title The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan
title_short The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan
title_full The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan
title_fullStr The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan
title_full_unstemmed The Prioritization of Strategic Alliance among Biopharmaceutical Companies in Taiwan
title_sort prioritization of strategic alliance among biopharmaceutical companies in taiwan
publishDate 2008
url http://ndltd.ncl.edu.tw/handle/77208370580070317324
work_keys_str_mv AT yiruchen theprioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan
AT chényírú theprioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan
AT yiruchen guónèishēngjìyīyàochǎnyècèlüèliánméngzhīyōuxiānyīnsùpínggū
AT chényírú guónèishēngjìyīyàochǎnyècèlüèliánméngzhīyōuxiānyīnsùpínggū
AT yiruchen prioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan
AT chényírú prioritizationofstrategicallianceamongbiopharmaceuticalcompaniesintaiwan
_version_ 1718266506172694528